Orgenesis Inc. announced the signing of a non-binding memorandum of understanding (MOU) with University of California, Davis (UC Davis). The MOU was signed by Orgenesis POC CA Inc., a Delaware corporation ("Orgenesis POC CA") incorporated by Orgenesis' POCare service subsidiary, Morgenesis LLC ("Morgenesis"), and The Regents of the University of California, on behalf of its Davis campus ("University"). The goal of the MOU is to progress towards a wider definitive agreement pursuant to which the University and Orgenesis POC CA expect to roll out Morgenesis' proprietary Orgenesis Mobile Processing Units and Labs™ ("OMPULs™?") throughout universities within the State of California.

Both Orgenesis, through Orgenesis POC CA, and the University, aim to roll out the OMPULs within the State of California in a staged approach. The first stage involves establishing and validating an OMPUL at UC Davis, anticipated to be within the first 12 months following execution of a definitive agreement between the parties. Thereafter, both parties will agree upon and develop a decentralized model of OMPUL placement in compliance with regulatory requirements, as well as commercialize and install OMPULs at other healthcare sites within the State of California.

The intent is to enable the development and manufacture of cell and gene therapies from Orgenesis, its partners, and UC Davis' partners. Orgenesis POC CA or its affiliates and the University may agree to develop and/or manufacture other therapies initiated from the University and/or third parties for point of care treatment of patients utilizing the OMPUL, subject to a further agreement(s). UC Davis originally signed a collaboration agreement to join Orgenesis' Point of Care ("POCare") Network on January 9, 2020.

UC Davis Health has been utilizing Orgenesis' Pocare platform to develop, commercialize and supply cell and gene products and therapies.